Skip to content
6-K

Foreign Interim / Material

INTELLIPHARMACEUTICS INTERNATIONAL INC.

0001654954-23-012269

← back to feed
Filed
Sep 26, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q1 2023 · Feb 28, 2023 −$14.18K
Operating Cash Flow Q1 2023 · Feb 28, 2022 −$560.58K
Cash And Equivalents Q1 2023 · Feb 28, 2023 $69.55K
Cash And Equivalents Q1 2023 · Nov 30, 2022 $83.72K
Stockholders Equity Q1 2023 · Feb 28, 2023 −$10.93M
Stockholders Equity Q1 2023 · Nov 30, 2022 −$10.58M
Stockholders Equity Q1 2023 · Feb 28, 2022 −$9.02M
Stockholders Equity Q1 2023 · Nov 30, 2021 −$8.16M
Total Liabilities Q1 2023 · Feb 28, 2023 $12.53M
Total Liabilities Q1 2023 · Nov 30, 2022 $12.01M
Current Assets Q1 2023 · Feb 28, 2023 $735.37K
Current Assets Q1 2023 · Nov 30, 2022 $492.51K
Total Assets Q1 2023 · Feb 28, 2023 $1.6M
Total Assets Q1 2023 · Nov 30, 2022 $1.43M
Sga Expense Q1 2023 · Feb 28, 2023 $138.84K
Sga Expense Q1 2023 · Feb 28, 2022 $260.86K
Rd Expense Q1 2023 · Feb 28, 2023 $448.17K
Rd Expense Q1 2023 · Feb 28, 2022 $543.99K
Net Income Q1 2023 · Feb 28, 2023 −$355.74K
Net Income Q1 2023 · Feb 28, 2022 −$880.97K
Operating Income Q1 2023 · Feb 28, 2023 −$301.4K
Operating Income Q1 2023 · Feb 28, 2022 −$772.92K
Revenue Q1 2023 · Feb 28, 2023 $326.34K
Revenue Q1 2023 · Feb 28, 2022 $83.41K